Eaton Vance Management Vir Biotechnology, Inc. Transaction History

Eaton Vance Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$19.08 - $26.7 $721,529 - $1.01 Million	-37,816 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$21.19 - $40.01 $798,778 - $1.51 Million	37,696 Added 31413.33%	37,816 $972,000
Q4 2021 Feb 14, 2022	SELL	$30.97 - $54.03 $526 - $918	-17 Reduced 12.41%	120 $0
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $1,361 - $2,127	39 Added 39.8%	137 $0
Q2 2021 Aug 16, 2021	SELL	$38.75 - $51.0 $7,943 - $10,455	-205 Reduced 67.66%	98 $5,000
Q1 2021 May 17, 2021	BUY	$26.34 - $83.07 $7,981 - $25,170	303 New	303 $16,000

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.